The FDA has accepted the supplemental new drug application for decitabine/cedazuridine plus venetoclax to treat adults with AML.

The Trump administration's recent travel and visa restrictions are preventing medical residents from starting their jobs in the US.

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

The FDA has published more than 200 complete response letters, sent as replies for applications submitted from 2020 to 2024.

This article was originally published on Stateline. The giant tax and spending bill President Donald Trump signed into law over the weekend includes the biggest health care spending cuts in U.S.

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited cont ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Mass firings and grant terminations have disrupted research and other operations at the National Cancer Institute.

Under the “One Big Beautiful Bill Act,” 10.9 million Americans would lose health insurance by 2034, according to estimates from the Congressional Budget Office.

The composition of the gut microbiome appears to be associated with treatment response in patients with pancreatic cancer, research suggests.

Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.